MedTrace Logo

Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects

NCT02765724 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2020-03-06

No results posted yet for this study

Summary

This is an open-label, parallel-group, single-dose study of the PK and safety of 400 mg pacritinib administered orally to patients with stable chronic liver disease and healthy control subjects.

Conditions

Interventions

DRUG

Pacritinib

Pacritinib 400 mg (4 capsules of 100 mg each), single dose, oral administration

Sponsors & Collaborators

  • SGS S.A.

    collaborator INDUSTRY

  • CTI BioPharma

    lead INDUSTRY

Principal Investigators

  • James Dean, MD, PhD · CTI BioPharma

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • Germany
  • Moldova

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02765724 on ClinicalTrials.gov